SciELO - Scientific Electronic Library Online

 
vol.38 número2Modulation of dendritic cell differentiation by lung tumor antigens índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista Colombiana de Ciencias Químico - Farmacéuticas

versão impressa ISSN 0034-7418versão On-line ISSN 1909-6356

Resumo

SANABRIA ROJAS, Andrea; MARTINEZ, José Ignacio  e  DIAZ ROJAS, Jorge Augusto. Colon cancer: Analysis of disease cost to III and IV stages in Cansercoop IPS. Rev. colomb. cienc. quim. farm. [online]. 2009, vol.38, n.2, pp.193-214. ISSN 0034-7418.

The cancer colon has an increased incidence in Colombia and is a leading causes of mortality and morbidity in this group of diseases with a high economic and emotional burden, from the standpoint of economic impact there is little information in the Colombian context, for this reason, this work makes a case study in a health institution providing services, applying the methodology of "Cost of Illness" based on the prevalence of disease. Aim: To estimate the whole costs, both direct and indirect to cancer colon; establishing a distribution resources to III and IV stages. Method: analysis cost of Illness was used in patients were diagnosed as having both III and IV stages with cancer colon, from January 2005 to October 2007; checking a base data in Cansercoop IPS. Results: 79 people were identified, 44 (III stage) and 35 (IV stage), 59.9% of all of them are women up to 60 years old and 58.2% belong to Salud Total. The total cost was $ 348.254.762, 98.4% were direct costs and 1.59% were indirect costs. Average cost for each patient was $ 1.700.816 (49.288-11.529.013), III stage and $ 7.653.742 (13.523-70.354.423), IV stage. 65.66% are medicines. Conclusions: the total costs, both III and IV stages were $ 77.143.347 and $ 271.111.415 in III stage and $182.570.717 in IV stage. This analysis can be considered as a preliminary study; however it means a step to subsequent economic health assessments.

Palavras-chave : colon cancer; analysis "cost of illness"; directs costs; indirect costs; total costs.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons